You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
复星医药(02196.HK)夥BioNTech向中国售1亿剂新型肺炎疫苗 提成65%
阿思达克 12-16 08:39
复星医药(02196.HK)公布,与BioNTech订立有关许可协议的第一号修订协议,修订许可协议项下有关新型肺炎疫苗产品於中国大陆、香港及澳门的销售提成条款,就由BioNTech供应的成品,复星医药产业与BioNTech分别按年度销售毛利的65%及35%的比率享有销售提成,另外就由BioNTech供应的大包装制剂,复星医药产业与BioNTech分别按年度销售毛利的60%及40%的比率享有销售提成。

另外BioNTech附属BioNTech Manufacturing GmbH、复星医药产业及BioNTech,就有关BioNTech Manufacturing向其於中国大陆供应新型肺炎疫苗产品订立供货协议,根据供货协议,在新型肺炎疫苗产品获得中国大陆上市批准,且复星医药产业根据供应协议下达相应订单的情况下,BioNTech Manufacturing承诺於2021年向中国大陆供应不少於1亿剂新型肺炎疫苗产品。

就首批5,000万剂新型肺炎疫苗产品的预付款,复星医药产业应在今年12月30日前支付金额为1.25亿欧元的部分首付款,其余1.25亿欧元之首付款应於新型肺炎疫苗产品在中国大陆获批上市後支付。复星医药产业应在新型肺炎疫苗产品交付後按照BioNTech Manufacturing发出的账单支付首批新型肺炎疫苗产品供应的余款,受限於根据供货协议条款按年进行最终结算。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account